Clinical Risk Assessment in the Antiphospholipid Syndrome: Current Landscape and Emerging Biomarkers.

about

Clinical Risk Assessment in the Antiphospholipid Syndrome: Current Landscape and Emerging Biomarkers.

Item

http://www.wikidata.org/entity/Q38657043

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Clinical Risk Assessment in th ...... scape and Emerging Biomarkers.

@en

type

Item

label

Clinical Risk Assessment in th ...... scape and Emerging Biomarkers.

@en

prefLabel

Clinical Risk Assessment in th ...... scape and Emerging Biomarkers.

@en

P1476

Clinical Risk Assessment in th ...... scape and Emerging Biomarkers.

@en

P2093

Keith R McCrae

http://www.w3.org/2001/XMLSchema#string

Shruti Chaturvedi

http://www.w3.org/2001/XMLSchema#string

P2860

Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines

Increased circulating platelet-leucocyte complexes and platelet activation in patients with antiphospholipid syndrome, systemic lupus erythematosus and rheumatoid arthritis

Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab

International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)

Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor

A novel pathway for human endothelial cell activation by antiphospholipid/anti-β2 glycoprotein I antibodies.

Antiphospholipid antibodies promote leukocyte-endothelial cell adhesion and thrombosis in mice by antagonizing eNOS via β2GPI and apoER2.

Antiphosphatidylethanolamine antibodies contribute to the diagnosis of antiphospholipid syndrome in patients with systemic lupus erythematosus.

Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients.

To the heart of the APS puzzle.

P2888

s11926-017-0668-2

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11926-017-0668-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1090685446

http://www.w3.org/2001/XMLSchema#string

P698

28711993

http://www.w3.org/2001/XMLSchema#string

P921

biomarker